HIGHLIGHTS
- who: Xiaofei Zhou from the Takeda Development Center Americas, Inc(TDCA), Lexington, MA, USA have published the paper: Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors, in the Journal: (JOURNAL)
- what: The aim was to assess the effect of multipledose administration of rifampin on the single-dose PK of pevonedistat in adult patients with advanced solid tumors.
- how: Since pevonedistat is a cytotoxic agent and cannot be administered to healthy subjects this study was conducted in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.